Isomorphic Labs is a British artificial intelligence company founded in 2021 as a spinout from Google DeepMind. The company applies predictive and generative AI to drug discovery, building on foundational work in structural biology including the AlphaFold system. Its unified drug design engine operates across multiple therapeutic areas and drug modalities, enabling much of the candidate identification process to be conducted computationally rather than experimentally.
The company maintains strategic partnerships with Eli Lilly, Novartis, and Johnson & Johnson. Its internal pipeline focuses on oncology and immunology. The technical work draws on an interdisciplinary team combining drug discovery specialists with machine learning researchers, treating biology as an information-processing system amenable to computational modelling and design.
Isomorphic Labs' approach centres on accelerating scientific discovery by shifting labour-intensive experimental work to in silico environments. The company has built AI models capable of designing novel molecules and predicting drug performance characteristics across complex biological phenomena.
